Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Tokyo, Japan; 3 Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; and 4 Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan Adenoviral gene transfer to hematopoietic stem cells (HSCs)/ progenitors would provide a new approach to the treatment of hematopoietic diseases and study of the hematopoietic system. We have previously reported that an adenovirus (Ad) vector composed of whole Ad serotype 35 (Ad35), which belongs to subgroup B, shows efficient gene transfer into human bone marrow CD34 + cells. However, Ad35 vector-mediated transduction into human HSCs/progenitors has not yet been fully optimized. In the present study, we have systematically examined promoter activity in the context of Ad35 vectors in human bone marrow CD34 + cells and primitive CD34 + subsets to optimize the transduction efficiency in human hematopoietic stem/progenitor cells. In the first of the transduction experiments, the improved in vitro ligation method was applied to Ad35 vector construction to allow for simple and efficient production of an E1/E3-deleted Ad35 vector. Using this method, we constructed a series of Ad35 vectors encoding the enhanced green fluorescence protein (GFP) under the control of a variety of strong viral and cellular promoters. Of the six types of promoters tested, significantly higher transduction efficiencies were achieved with the human elongation factor 1a promoter (EF1a promoter), the human cytomegalovirus (CMV) immediateearly 1 gene enhancer/b-actin promoter with b-actin intron (CA promoter), and the CMV promoter/enhancer with the largest intron of CMV (intron A) (CMVi promoter) in the human CD34 + cells and the immature subsets (CD34   +   CD38 low/À and CD34 + AC133 + subsets). In particular, the CA promoter was found to allow for the highest transduction efficiencies in both the whole human CD34 + cells and the immature hematopoietic subsets. Furthermore, the CA promoter-mediated GFP-expressing cells differentiated into progenitor cells of all lineages. These results indicate the construction of an optimized Ad35 vector
Introduction
Hematopoietic stem cells (HSCs) have the potential for self-renewal and multilineage differentiation into all mature blood cells. Hence, efficient transduction into HSCs would afford the opportunity to treat a number of diseases that result from abnormal blood cell function, and would be a powerful tool for study of the regulation of proliferation, differentiation, and trafficking of HSCs. For gene transfer into HSCs, moloney-derived retrovirus vectors and lentivirus vectors are often used, although the transduction efficiencies of the retrovirus vectors are disappointingly low in immature HSC/progenitors, probably due to the quiescent state of HSCs and the lack of suitable receptors for vector binding. 1, 2 Lentivirus vectors have recently shown promise, 3, 4 but their safety remains to be established.
Among the various types of vectors, adenovirus (Ad) vectors have been widely used for delivery of foreign genes in not only experimental studies but also clinical trials. Advantages which make Ad vectors an attractive vehicle for gene transfer include the ability to easily prepare high-titer stocks of purified vectors, efficient escape from the endosome, and the ability to transport their DNA genome into the nucleus, allowing for efficient transduction in quiescent cells. However, the utility of commonly used Ad vectors, which are based on Ad serotype 2 (Ad2) or Ad serotype 5 (Ad5) belonging to subgroup C, for transduction into human CD34 + cells has been limited 5, 6 because a primary receptor for Ad2 and Ad5, coxsackievirus and adenovirus receptor (CAR), and second receptors, a v b 3 -and a v b 5 -integrins, are not expressed at sufficient levels in human CD34 + cells. 5, 7, 8 In contrast, it has been shown that Ad serotype 35 (Ad35), which belongs to subgroup B, is efficient at binding to human CD34 + cells and hematopoietic cell lines. 5, 9 We have therefore developed a novel Ad vector, Ad35 vector, which is composed of whole Ad35, and have demonstrated that Ad35 vectors achieve higher levels of transduction efficiency without significant toxicity in human bone marrow CD34 + cells than both conventional Ad5 vectors and chimeric Ad5F35 vectors, which are fiber-substituted Ad5 vectors containing Ad35 fiber proteins. 10 Ad35 recognizes CD46 (membrane cofactor protein) as a cellular receptor, 11, 12 and CD46 is ubiquitously expressed in almost all human cells except for erythrocytes, 13, 14 including human cord blood CD34 + cells. 15 Therefore, human CD34 + cells would be considered to be a suitable target for Ad35 vectors.
In addition to receptor expression in target cells, the choice of promoters that drive expression of introduced genes is another crucial determinant for transduction efficiency. Optimization of the promoter leads not only to increased transgene expression but also to decreased vector dose and side effects. A variety of promoters have been used for transduction into human CD34 + cells, including the phosphoglycerate kinase 1 promoter (PGK promoter), 16 the human cytomegalovirus immediateearly region promoter/enhancer (CMV promoter), 17, 18 and the CMV immediate-early enhancer/the chicken b-actin promoter with the b-actin intron sequence (CA promoter). 8 However, few studies have simultaneously compared the relative strength of various types of promoters in human CD34 + cells, 19 
Results

Construction of E1/E3-deleted Ad35 vectors by the improved in vitro ligation method
To construct E1/E3-deleted Ad35 vectors simply and efficiently, the improved in vitro ligation method was applied to the construction of Ad35 vectors. This method, which was developed by Mizuguchi and Kay, 20, 21 is a simple and efficient method by which conventional Ad5 vectors can be constructed. First, all of the E1a region and most of the E1b region were deleted to make the Ad35 vectors replication-incompetent. Then, the three unique restriction sites (I-CeuI, SwaI, and PISceI) were introduced into the E1 deletion site to efficiently insert foreign genes into the E1 deletion site of the vector plasmid by a single in vitro ligation. The ICeuI and PI-SceI sites were used for insertion of foreign genes, while the SwaI site was used to reduce the generation of parental, nonrecombinant plasmid. Next, to increase the packaging capacity of the Ad35 vector genome, most of the E3a and E3b regions were deleted. The resulting vector plasmids, pAdMS2, pAdMS3, and pAdMS4, contain the complete Ad35 genome minus the E1 (pAdMS2) or E3 region (pAdMS3) or E1/E3 region (pAdMS4) (Figure 1 ). Approximately 3 and 1.9 kb of the E1 and E3 regions, respectively, were deleted in pAdMS4.
The Ad35 vector plasmids containing a green fluorescence protein (GFP) gene under the control of a variety of promoters were produced by in vitro ligation of I-CeuI/ PI-SceI-digested pAdMS4 and the shuttle plasmids containing a GFP expression cassette. SbfI-linearized Ad35 vector plasmids were transfected into VK10-9 cells (293 cells expressing Ad5 E4 proteins as well as E1 proteins), 22 and the cells were cultured for 10-14 days to produce recombinant Ad35 vectors, followed by the routine method for Ad5 vector preparation. VK10-9 cells can support the replication of Ad35 vectors; however, Ad35 vectors can not grow on 293 cells, as described previously. 10 The final yields of the Ad35 vectors were equivalent to those described previously. 10, 23 Relationship between CD46 expression and transduction efficiency in human bone marrow CD34 + cells
Recently, the complement regulatory protein CD46 has been identified as a cellular receptor for Ad subgroup B. 11, 12 To study the role of CD46 in Ad35 vector-mediated transduction into human bone marrow CD34 + cells, we evaluated the relationship between CD46 expression levels and the transduction efficiencies of Ad35 vector containing the CMV promoter. The CMV promoter is generally regarded as one of the most powerful Optimization of promoter in Ad35 vectors into human hematopoietic progenitors F Sakurai et al promoters 24 and is widely used in transduction experiments. As shown in Figure 2a , almost all the bone marrow CD34 + cells expressed high levels of CD46, similar to the cord blood CD34 + cells. 15 Significant amounts of CD46 were detected in all the CD34 + cells from three different donors (data not shown). In the transduction experiments using Ad35 vector containing the CMV promoter, the percentage of GFP-positive cells was proportional to the vector concentration at the lower vector doses of 1000-6000 VP/cell (Figure 2b) . However, despite the high levels of CD46 expression, the transduction efficiencies of the Ad35 vector did not correlate with the vector concentrations at the higher vector dose reaching a plateau at more than 12 000 VP/cell. There was no correlation between the levels of CD46 expression and the GFP expression levels ( Figure 2c ). These data indicate that factors other than the CD46 expression levels also determine the transduction efficiencies of Ad35 vectors in human bone marrow CD34 + cells.
Transduction with Ad35 vectors containing various types of promoters in human bone marrow CD34 + cells
The refractoriness of the human CD34 + cells to Ad35 vector-mediated transduction might be due to promoters that drive expression of a foreign gene. To examine the promoter activities in the CD34 + cells, we investigated the transduction efficiencies of the Ad35 vectors containing various types of promoters in the CD34 + cells at 6000 VP/cell. The following promoters were tested: the CMV promoter, the EF1a promoter, the CA promoter, the mouse PGK promoter, the murine stem cell virus (MSCV) long terminal repeat (LTR) promoter (MSCV promoter), and the CMV promoter/enhancer containing the largest intron of CMV (intron A) (CMVi promoter). Of the six types of promoters, the CA, EF1a, and CMVi promoters were found to allow higher levels of GFP expression than the CMV, PGK, and MSCV promoters ( + cells with Ad35 vector containing the CA promoter at 6000 VP/cell for 48 h led to an increase in GFP-positive cells up to 67% (data not shown). These data indicate that the transduction efficiencies in human bone marrow CD34 + cells are largely dependent on the promoter and that the CA promoter is the most active in CD34 + cells among the six types of promoters examined in the present study.
Next, to determine whether the Ad35 vectors had infected the CD34 + cells that did not express GFP, the + subsets). These data indicate that the CA, EF1a, and CMVi promoters mediate the higher transduction efficiencies and that the CA promoter is the most efficient in these immature CD34 + subpopulations.
CA promoter activity in the colony-forming hematopoietic progenitors
To evaluate the gene expression potential of the CA promoter in colony-forming hematopoietic progenitors, the transduced cells were sorted into GFP-positive and -negative cells following transduction with the Ad35 vector containing the CA promoter, and colony-forming assays were then performed for the sorted GFP-positive and -negative cells. Values indicating the colony-forming unit (CFU) content of the sorted cells 14 days after plating are shown in Table 1 . Comparing the total number of colonies derived from the GFP-positive cells with those from the uninfected cells and the GFPnegative cells, it appears that the GFP-positive cells formed almost the same total numbers of colonies as the uninfected cells and the GFP-negative cells. CFUgranulocyte-macrophage (CFU-GM) colonies were grown without significant reduction from the CA promoter-mediated GFP-positive cells, compared with Optimization of promoter in Ad35 vectors into human hematopoietic progenitors F Sakurai et al the GFP-negative cells, although the growth of burstforming units-erythroid (BFU-E) colonies was slightly impaired in the GFP-positive cells. CFU-granulocyte erythrocyte monocyte macrophage (CFU-Mix) colonies, which are derived from the most primitive hematopoietic progenitors, were also found in GFP-positive cells. These data suggest that the CA promoter would be significantly active in immature colony-forming progenitors. However, the size of colonies from both GFPpositive and -negative cells appeared to be smaller than that in uninfected cells (data not shown), suggesting that exposure to Ad35 vectors slightly impairs the growth of colony-forming bone marrow hematopoietic progenitors under these conditions.
Discussion
The choice of a promoter to drive transgene expression is important in gene transfer experiments. Currently, a few systematic examinations of promoter activities have been carried out in gene transfer experiments in vivo [28] [29] [30] and low/À subsets were transduced at 6000 VP/cell for 6 h, washed, and resuspended in medium. After 48 h, GFP expression was measured by flow cytometry. All data represent the means7s.d. of two experiments.
Optimization of promoter in
+ cells and immature CD34 + subsets.
In the present study, we examined the following promoter activities in human bone marrow CD34 + cells: the CMV, EF1a, CMVi, CA, MSCV, and PGK promoters, which are widely used in transduction experiments.
Comparison of the six types of promoters showed that a significant increase in GFP-positive cells was obtained with the EF1a, CMVi, and CA promoters. Among these three promoters, the CA promoter was the most efficient at transducing human bone marrow CD34 + cells ( Figure  3 ) and immature CD34 + subsets (CD34 + CD38 low/À and CD34 + AC133 + subsets) ( Figures 5 and 6 ) under the condition employed. Furthermore, the CA promotermediated GFP-positive cells formed nearly the same numbers of colonies as uninfected cells in the colony assay ( Table 1 ). The powerful activity of the CA promoter has been demonstrated in important target cells for gene therapy, including dendritic cells, 32 lymphocytes, 32 and hepatocytes. 33 In addition, earlier work with the CA promoter noted heightened transgene expression in immature cells. Okabe et al 34 have demonstrated that the CA promoter functions in the embryos of transgenic mice. Efficient transgene expression has also been achieved with the CA promoter in murine embryonic stem cells. 35, 36 The data described above indicate that the CA promoter would be the promoter of choice for high levels of transgene expression in immature cells, including HSCs/progenitors.
The CMV promoter is one of the strongest promoters and is currently in wide use for transient gene expression experiments. However, the CMV promoter did not mediate high levels of GFP expression in the CD34 + cells (Figure 2b ), immature subsets ( Figures 5 and 6) , and colony-forming CD34 + progenitors (data not shown). Several groups have demonstrated that the CMV promoter does not allow for high transduction efficiencies in human CD34 + cells 3, 19 and murine embryonic stem cells, 36, 37 suggesting that the CMV promoter might not be appropriate for immature cells. However, the inclusion of intron A into the CMV promoter (CMVi promoter) largely increases GFP expression in the CD34 + cells as well as immature CD34 + subsets. The b-actin intron is also included in the CA promoter. These data suggest that an intron may be a key element for efficient transgene expression in human CD34
+ cells, although a detailed mechanism for enhancement of transgene expression by intron A in CD34 + cells has not yet been elucidated.
Recently, the human membrane cofactor protein CD46 has been shown to be a cellular receptor for subgroup B Ad, including Ad35. 11, 12 CD46 is a single-chain type I transmembrane glycoprotein that is expressed in almost all human cells. 13, 14 The ubiquitous expression of CD46 leads to a broad tropism of Ad35 vectors toward human cultured cells compared with Ad5 vectors. 23 Expression levels of CD46 on the cells appear to correlate with the affinity of Ad35 for the cells, which is similar to the relationship between CAR expression levels on the cells and the transduction efficiencies of Ad5 vectors, as reported below. Segerman et al 9 have demonstrated almost 100% binding of Ad35 to human hematopoietic cell lines, Jurkat, K562, and HL-60 cells, which express sufficient levels of CD46. 38, 39 The transduction efficiencies of the chimeric Ad5F35 vector, which is an Ad5-based vector containing an Ad35 fiber shaft and knob, have been found to increase progressively with CD46 expression density on a panel of CHO cells stably expressing CD46. 40 Shayakhmetov et al 5 have reported the efficient attachment and internalization of Ad35 in human bone marrow CD34 + cells, which express high level of CD46 (Figure 2a) . In this study, however, the transduction efficiencies in the CD34 + cells unexpectedly did not increase proportionally with the increased dose of Ad35 vectors, despite the high expression levels of CD46 (Figure 2b ). Even the CA promoter, which was the most efficient in this study, did not mediate more than 70% of GFP-positive cells at the increased dose (data not shown). The limitation of the transduction efficiencies in the CD34 + cells is likely due to the promoter activities that direct transgene expression. We have demonstrated that similar amounts of Ad35 vector genome could be detected in both GFP-positive and -negative cells ( Figure  4) . These results suggest that Ad35 vectors would interact with all of the CD34 + cells via CD46; however, the promoters examined here do not function in all infected CD34 + cells. It is well known that human CD34 + cells are heterogeneous. With the GFP-negative cells À cell frequency occurred during culture; however, these cells lost the potential to repopulate in the NOD/SCID mouse and to form colonies in the colony-forming assay, respectively. We confirmed that the expression levels of CD38 and AC133 decreased after a 2-day culture (data not shown). As such, the CD34 + cells might have to be sorted before transduction to truly evaluate the transduction efficiencies in primitive hematopoietic subsets. In addition, because the CD34 + cells may differentiate during culture and Ad35 vectors may infect differentiated cells efficiently, Ad35 vectors in the present study were incubated with the CD34 + cells for 6 h and the cells were then washed to remove Ad35 vectors. More efficient transduction with Ad35 vectors was achieved when the CD34 + cells were continuously cultured with Ad35 vectors for 48 h (data not shown), as reported previously. 10 Various methods have been established for feasible generation of Ad vectors. 46 Among these methods, the improved in vitro ligation method, which was developed by Mizuguchi and Kay, 20, 21 is a simple and efficient method based on plasmid construction. To efficiently construct a series of Ad35 vectors, an improved in vitro ligation system was applied to construction of replication-incompetent E1/E3-deleted Ad35 vectors. We have previously constructed Ad35 vector plasmids by gel purification of DNA fragments and two-step in vitro ligation. 10 Reddy et al 47 have also constructed Ad35 vector plasmids by several steps of in vitro ligation of DNA fragments. Vogels et al 48 and Gao et al 49 have reported construction of recombinant Ad35 vectors by homologous recombination in 293-derived cell lines and PER.C6 cells stably expressing Ad35 E1B 55K, respectively. All of these methods described above are timeconsuming and inefficient. Using the improved in vitro ligation method, we more rapidly obtained yields of Ad35 vectors similar to those reported previously. 10 In addition, based on the sequence information of the Ad35 E1 and E3 regions, the E1 deletion size has been increased and most of the E3 region has been deleted in pAdMS4, leading to an increase in the packaging capacity. The increase in the deletion size in the E1 and E3 regions did not reduce the transduction efficiencies of Ad35 vectors (data not shown). Further deletions in the E1 and E3 coding regions must make it possible to insert larger foreign genes into the Ad35 vectors.
As the Ad genome does not integrate into the host genome, transgene expression via Ad vectors can occurr transiently, which is suitable for ex vivo manipulation of HSCs and the study of gene functions. This property also results in a low risk of insertion mutagenesis, but stable transgene expression is not allowed. To address this limitation, several groups have developed hybrid Ad vectors such as Ad/adeno-associated virus vectors, which can integrate viral genome into the host genome. [50] [51] [52] The Ad35 vector would be a promising framework for the development of these improved vectors.
In summary, we have demonstrated that the EF1a, CMV promoter containing intron A, and the hybrid CA promoter is superior at transducing human bone marrow CD34 + cells in the context of Ad35 vector. In particular, the CA promoter functions most efficiently in CD34 + cells and immature CD34 + subsets. The results of our study provide valuable information regarding gene transfer into HSCs.
Materials and methods
Plasmids
Vector plasmids pAdMS2, -3, and -4 were constructed as follows. The SbfI/PstI fragment of pFS2-Ad35-7, 10 which has the left end of the Ad35 genome (bp 1-367 and 2917-3670) with an E1 deletion, was ligated with the SbfI site of pFS2, 10 resulting in pFS2-Ad35-9. (The end of the SbfI site is compatible with a PstI site.) pFS2-Ad35-9 was cut by PacI and BamHI, and ligated with oligonucleotides 1 (5 0 -TATAACTATAACGGTCCTAAGGTAGCGAATTTAAA TATCTATGTCGGGTGCGGAGAAAGAGGTAATGAA ATGGCA-3 0 ) and 2 (5 0 -GATCTGCCATTTCATTACCT CTTTCTCCGCACCCGACATAGATATTTAAATTCGCTA CCTTAGGACCGTTATAGTTATAAT-3 0 ) (I-CeuI, SwaI, and PI-SceI recognition sequences are noted by underlining, italics, and bold, respectively), resulting in pFS2-Ad35-10, which contains I-CeuI, SwaI, and PI-SceI sites in the E1 deletion site of the Ad35 genome. The SbfI/PstI fragments of pFS2-Ad35-7 and pFS2-Ad35-10 were then ligated, resulting in pFS2-Ad35-11. The SbfI/AscI fragment of pFS2-Ad35-11 was exchanged with the SbfI/AscI fragment of pAdMS1, 10 which clones the whole Ad35 genome, resulting in pAdMS2-1. The NotI site of pAdMS2-1 was changed into an SbfI site by using oligonucleotide 3 (5 0 -GGCCCCTGCAGG-3 0 ) (the SbfI recognition sequence is underlined), resulting in pAdMS2. To delete the E3 region in the Ad35 genome, the BamHI/NotI fragment of pHM15-Ad35-1, 10 which has the right end of the Ad35 genome (bp 29732 -right end of the genome), was cloned into BamHI/NotI sites of a shuttle plasmid pFS1, which contains multicloning sites composed of SalI/SbfI/EcoRI/BamHI/SwaI/NotI sites, creating pFS1-Ad35-1. pFS1 was constructed by ligation of XbaI/SacI-digested pGEM7Zf(+) (Promega Optimization of promoter in Ad35 vectors into human hematopoietic progenitors F Sakurai et al
Corp., MA, USA) with the oligonucleotides containing the multi-cloning sites. The SalI/EcoRI fragment of pHM15-A35-1 (bp 23583-27760) was inserted between the SalI/EcoRI sites of pFS1-Ad35-1, resulting in pFS1-Ad35-2. pFS1-Ad35-2 was then cut by EcoRI/BamHI and ligated with oligonuclotide 4 (5 0 -AATTGGCCACG TAGGCC-3 0 ) and 5 (5 0 -GATCGGCCTACGTGGCC-3 0 ) (SfiI recognition sequence is underlined), resulting in pFS1-Ad35-9. The SalI/NotI fragment of pFS1-Ad35-9 was ligated with the SalI/NotI fragment of pHM14-Ad35-1, creating pHM14-Ad35-3. pHM14-Ad35-1 was constructed by cloning of the EcoRI/KpnI fragment (bp 21945-29545) of the Ad35 genome into the EcoRI/KpnI sites of pHM14. 53 The EcoRI/NotI fragment of pHM14-Ad35-3 was ligated with the EcoRI/NotI fragment of pAdMS1, resulting in pAdMS3-1. The NotI site of pAdMS3-1 was changed into an SbfI site by using oligonucleotide 3, resulting in pAdMS3. The SbfI/AscI fragment of pFS2-Ad35-11 was ligated with the SbfI/AscI fragment of pAdMS3-1, creating pAdMS4-1. The NotI site of pAdMS4-1 was changed into a SbfI site by using oligonucleotide 3, resulting in pAdMS4. Shuttle plasmids containing a variety of promoters were constructed by changing the CMV promoter of pHMCMV5 21 into another type of promoter, including the EF1a promoter, the CA promoter, the mouse PGK promoter, the MSCV promoter, and the CMVi promoter. The EF1a promoter is derived from pEF1a/myc/nuc (Invitrogen, Carlsbad, CA, USA). The CMVi promoter is derived from pGeneGrip (Gene Therapy Systems, San Diego, CA, USA). The composite CA promoter and PGK promoter were kindly provided by Dr J Miyazaki (Osaka University, Osaka, Japan) and Dr MA Kay (Standford University, CA, USA), respectively. The MSCV promoter was a kind gift of Dr RG Hawley (American Red Cross, MD, USA).
E1/E3-deleted Ad35 vectors expressing enhanced GFP
To construct the plasmid for a recombinant E1/E3-deleted Ad35 vector containing a CMV promoter-driven GFP expression cassette, pHMCMV-GFP1 54 and pAdMS4 were digested with I-CeuI and PI-SceI. The digested pAdMS4 was ligated with the I-CeuI/PI-SceI fragment of pHMCMV-GFP1 containing a GFP expression cassette, resulting in pAdMS4-CMVGFP. pAdMS4-CMVGFP was linearized by the digestion with SbfI. The linearized DNA was transfected into VK10-9 cells (kindly provided by Dr V Krougliak), 22 which are 293 cells expressing the E4 proteins of Ad5 as well as the E1 proteins. A cytopathic effect (CPE) was observed 10-14 days after transfection, and the virus was then amplified in VK10-9 cells and purified by the conventional method for Ad5 vector preparation. For the preparation of recombinant E1/E3-deleted Ad35 vectors containing various types of promoters, a GFP gene was cloned into multi-cloning sites in the shuttle plasmids containing various types of promoters, and the Ad35 vectors were then prepared by methods similar to those described above.
Transduction experiment
Human bone marrow CD34 + cells were purchased from Biowhittaker, Inc., Walkersville, MD, USA. The cells were recovered from the frozen stock, suspended in StemSpant 2000 containing cytokine cocktail StemSpant CC100 (human Flt-3 ligand (100 ng/ml), human stem cell factor (100 ng/ml), human interleukin (IL)-3 (20 ng/ ml), and human IL-6 (20 ng/ml)) (StemCell Technologies Inc., Vancouver, BC, Canada), and were seeded into a 48-or 96-well plate (1-5 Â 10 4 cells/well). The cells were transduced with the GFP-expressing Ad35 vectors at the indicated VP/cell 16-18 h after seeding. At 6 h after incubation, the cells were washed to remove the Ad35 vectors and resuspended in the medium. At 48 h after transduction, 10 4 cells per sample were analyzed for GFP expression by flow cytometry on a FACSCalibur flow cytometer using CellQuest software (Becton Dickinson, Tokyo, Japan).
Flow-cytometric analysis of CD46 expression
Human bone marrow CD34 + cells were suspended in staining buffer containing fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD46 antibody (Pharmingen, San Diego, CA, USA). After washing with the sorting solution, the stained cells (10 4 cells) were analyzed using a FACSCalibur and CellQuest software (Becton Dickinson). For simultaneous analysis of GFP and CD46 expression, the transduced cells were incubated with mouse anti-human CD46 antibody (Pharmingen). Subsequently, the cells were washed and incubated with phycoerythrin (PE)-conjugated goat anti-mouse IgG second antibody (Pharmingen). After washing with the sorting solution, the analysis was performed as described above.
Real-time quantitative PCR
Human bone marrow CD34 + cells were incubated with the Ad35 vectors at 6000 VP/cell, and control cells were incubated without the Ad35 vectors. After a 6-h incubation, the medium was changed to remove the Ad35 vectors. At 48 h after transduction, the cells were harvested, pelleted, and washed gently. The cells were then sorted into GFP-positive and -negative fractions using a FACSVantage SE (Becton Dickinson). Sort purities were greater than 90% for both GFP-positive and -negative fractions. The sorted cells were treated with trypsin and DNase, followed by washing to remove the extracellular vector genome. Total DNA, including the Ad35 vector DNA, was extracted from the GFPpositive and -negative cells using a Tissue DNeasy Kit (Qiagen, Valencia, CA, USA). The quantitative real-time PCR was performed with 2.5 ng of sample DNA, 0.5 mM each primer, 0.16 mM TaqMan probe, and 25 ml of TaqMan universal PCR master mix (Applied Biosystems, Foster City, CA, USA) in a final volume of 50 ml using the ABI Prism 7000 sequence detection system (Applied Biosystems). The PCR was initially denatured at 951C for 10 min and then subjected to cycles of 951C for 15 s and Optimization of promoter in Ad35 vectors into human hematopoietic progenitors F Sakurai et al 601C for 1 min. The reaction was carried out for 50 cycles. Primers for amplification were located in the pIX region of Ad35 genome. The sequences of the primers and probe used were as follows: forward, 5 0 -TGGATGGAAG ACCCGTTCAA-3 0 ; reverse, 5 0 -CGTCCAAAGGTGAAG AACTTAAAGT-3 0 ; probe, 5 0 -FAM-CGCCAATTCTTC AACGCTGACCTATGC-TAMRA-3 0 . These sequences were designed using Primer Express softeware version 1.0 (Applied Biosystems), and it was confirmed that they amplified the products of desired size. The Ad35 vector plasmid pAdMS4 was used as a standard. For human b-actin quantification, b-actin control reagent (Applied Biosystems) was used.
Purification of immature CD34 + subpopulations
Human bone marrow CD34 + cells were incubated with PE-conjugated mouse anti-human AC133 monoclonal antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) or FITC-conjugated mouse anti-human CD38 monoclonal antibody (eBioscience, San Diego, CA, USA) immediately after the cells were recovered from the frozen stock. After washing, cell sorting was performed using a FACSVantage SE (Becton Dickinson). Sorting gates were set to sort the CD38 low/À and AC133 + subpopulations. Sort purities were greater than 80% for both CD38 low/À and AC133 + AC133 + cells were transduced with the Ad35 vectors at 6000 VP/cell, as described above.
Colony-forming assay
The GFP-positive and -negative cells were recovered 48 h after transduction with the Ad35 vector containing the CA promoter, as described above. In all, 1000 cells of each fraction were then plated in a 35-mm dish containing Methocult H4444 methylcellulose medium (erythropoietin; 3 U/ml, stem cell factor; 50 ng/ml, GM-CSF; 10 ng/ml, IL-3; 10 ng/ml) (Stem Cell Technologies). After 14 days of incubation at 371C in a 5% CO 2 incubator, CFU-GM, BFU-E, and CFU-Mix colonies were enumerated under a microscope. The experiments were performed in duplicate. Uninfected cells were also sorted into a GFP-negative fraction and treated as described above.
